Acasunlimab
Modify Date: 2024-04-02 19:56:39
Acasunlimab structure
|
Common Name | Acasunlimab | ||
|---|---|---|---|---|
| CAS Number | 2253937-12-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AcasunlimabAcasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer[1][2]. |
| Name | Acasunlimab |
|---|
| Description | Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) 促进树突状细胞和 T 细胞之间的相互作用并增强 T 细胞活化[1]。 Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) 在体外诱导剂量依赖性、条件性 T 细胞增殖和细胞因子产生，并增强抗原特异性 T 细胞介导的细胞毒性[1]。 |
| In Vivo | Acasunlimab (5 mg/kg; i.v.; 每周两次，共三个周期) 在双敲入 (dKI) 转基因 C57BL/6 小鼠中具有抗肿瘤活性并抑制肿瘤生长[1]。 Animal Model: Double knock-in (dKI) transgenic C57BL/6 mice[1] Dosage: 5 mg/kg Administration: Intravenous injection; twice weekly for three cycles Result: Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice. |
| References |
| No Any Chemical & Physical Properties |